KRYS - Company ID 0001711279
The table below shows Krystal Biotech, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | $116.36M | $97.80M | $96.04M | $88.18M | $83.84M | $70.28M |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $15.33M | $14.59M | $14.41M | $14.26M | $13.51M | $15.58M |
Krystal Biotech, Inc. reported annual revenue of $389.13M for fiscal year 2025. That is up 33.9% from $290.51M in fiscal 2024. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $41.01M |
| $37.58M |
| $35.16M |
| $32.65M |
| $28.67M |
| $27.63M |
| Operating income | $53.69M | $41.37M | $39.31M | $36.25M | $22.47M | $8.57M |
| Income tax | $5.51M | -$31.40M | $8.44M | $7.86M | $2.59M | $477.00K |
| Net income | $55.93M | $79.36M | $38.33M | $35.73M | $27.18M | $15.57M |
| EPS (diluted) | $1.83 | $2.66 | $1.29 | $1.20 | $0.91 | $0.53 |